// App-Quantinova.ai

: FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.

Researchers

Presenter

  • Srikala S. Sridhar

Principal Investigators

  • Nicholas Power

  • Rodney H. Breau

  • Susanna Y. Cheng

  • Gregory Russell Pond

  • Peter W. M. Chung

  • Ur Metser

  • Mark Norman Levine

  • Som D. Mukherjee

Medical Centers

  • Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Juravinski Cancer Center, Department of Oncology, McMaster University, Hamilton, ON, Canada

  • London Health Sciences Center, London, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • The Ottawa Hospital, Ottawa, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • Methotrexate

  • Gemcitabine

  • Vinblastine

  • Adriamycin injection

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • NA

Study Id's

  • NCT02462239

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved